N
NSE
14,468.70
Last Updated on 01 Aug 2025 at 19:35
Open at
14,845.65
52W High
15,108.80
52W Low
12,561.70
Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.
High
14,847.90
Low
14,447.50
Open at
14,845.65
Prev Close
14,880.25
Volumes
0
Avg Price
0.00
Lower Circuit
0.00
Upper Circuit
0.00
Quantity
0
Time
19:35:58
3 M High
15,079.85
3 M Low
13,445.85
1 Yr High
15,108.80
1 Yr Low
12,561.70
3 Yr High
15,108.80
3 Yr Low
8,920.90
5 Yr High
15,108.80
5 Yr Low
8,920.90
Positive Stocks
1
Negative Stocks
18
Neutral Stocks
1
Cipla Denies Awareness of Trump Letters Report Amid Pharma Stock Decline
Cipla responded to reports suggesting pharmaceutical stocks fell due to Trump sending letters to 17 global drug companies requesting lower prices. The company denied having awareness of this news and stated there is no undisclosed information behind the stock price changes.
Apollo Hospitals Subsidiary Directed to Pay INR 4.96 Crore for Foreign Exchange Rule Violation
Apollo Hospitals Enterprise Limited disclosed that its subsidiary Apollo Healthco Limited has been directed by the Reserve Bank of India to deposit INR 4,95,50,000 for compounding a contravention of foreign exchange management rules. The RBI order dated July 31, 2025 relates to violation of Rule 4 read with Rule 2(k) of Foreign Exchange Management (Non-debt Instruments) Rules, 2019. Apollo Healthco had filed a compounding application with RBI regarding this contravention. The company stated there is no impact on financial, operational or other activities due to this order, and no further claims, penalties or proceedings are pending. The company remains in compliance with all applicable regulations and confirmed this development does not impact operations, financial health or future outlook.
Granules India Receives One Procedural Observation from US FDA Pre-Approval Inspection
Granules India announced that the US FDA has completed a pre-approval inspection at one of the company's facilities. The inspection resulted in one procedural observation being issued to the company.
Abbott India Pays Rs. 2 Lakh Penalty to RBI for Exceeding Foreign Investment Limits
Abbott India Limited received a Compounding Order from the Reserve Bank of India's Foreign Exchange Department on July 31, 2025, requiring the company to pay Rs. 2,00,000 as penalty. The violation involved foreign investment in the company exceeding 75% due to secondary market transactions on stock exchanges without obtaining prior government approval, contravening foreign exchange laws. The company will deposit the compounding amount as directed. Once the compounding process is closed, Abbott India will be able to receive investment from foreign institutional investors up to the prescribed limit.
Sun Pharma Shares Drop 4% After Trump Demands Drug Price Cuts from Major Pharmaceutical Companies
Sun Pharma shares declined 4% after initially falling 6%, leading losses in the Nifty Pharma index following US President Donald Trump's letters to 17 major pharmaceutical companies demanding lower drug prices. Trump's letter required companies to charge the US similar rates to other countries for new medicines and lower Medicaid costs for existing drugs, with 60 days given for voluntary compliance. Sun Pharma derives around 20% of its revenues from innovative drugs sold in the US and had not received such communication as of their last quarterly conference call. The Trump administration is seeking most favoured nation treatment for Medicaid pricing to match rates charged in other wealthy developed nations. Other pharmaceutical stocks also declined, with Aurobindo Pharma, Gland and Granules India falling 2-3%. Most Indian generic companies face limited impact as they don't sell branded generics or innovator drugs.
View More
Period | Simple | Signal |
---|---|---|
5-SMA | 14,859.44 | Bearish |
10-SMA | 14,770.12 | Bearish |
20-SMA | 14,700.20 | Bearish |
50-SMA | 14,381.11 | Bullish |
100-SMA | 14,041.59 | Bullish |
200-SMA | 14,081.46 | Bullish |
Indicator | Value | Action |
---|---|---|
RSI(14) | 44.73 | Neutral |
ATR(14) | 180.31 | Volatile |
STOCH(9,6) | 72.22 | Neutral |
STOCH RSI(14) | 47.28 | Neutral |
MACD(12,26) | -17.57 | Bearish |
ADX(14) | 21.76 | Weak Trend |
Summary of Technical Indicators for NIFTY HEALTHCARE
NIFTY HEALTHCARE Gainers | LTP | Change% | Weightage | Market Cap (Cr.) | PE Ratio | 52W High | 52W Low |
---|---|---|---|---|---|---|---|
F Fortis Healthcare | 859.25 | 0.21% | 3.294% | ₹ 64,733.90 | 76.76 | 859.95 | 480.55 |
M Max Healthcare Institute | 1,246.00 | 0.00% | 6.164% | ₹ 1,21,129.50 | 106.86 | 1,314.30 | 836.60 |
Sectors | Companies | Weightage | Market Cap (Cr.) |
---|---|---|---|
Healthcare | 17 | 85.05% | 16,71,302.20 |
Healthcare Services | 3 | 14.95% | 2,93,673.10 |
Close Price
Volume
NIFTY HEALTHCARE share price in last 10 trading sessions
Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 | -7.78% | -8.00% | 7.85% | 2.72% | -1.16% | 4.13% | 2.88% | -2.77% | NA | NA | NA | NA | -3.23% |
2024 | 7.37% | 4.63% | 0.91% | -0.70% | -1.50% | 6.62% | 9.34% | 5.50% | 1.69% | -2.20% | -2.09% | 5.84% | 40.55% |
2023 | 0.00% | 4.91% | 2.54% | -4.77% | 11.17% | 3.39% | NA | NA | NA | NA | NA | NA | 0.00% |
1 Week
1 Month
3 Month
6 Month
9 Month
1 Year
2 Years
3 Years
4 Years
5 Years
1 Week
1 Month
3 Month
6 Month
9 Month
Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.
Name | LTP | Change | Change % | 1M Returns | 3M Returns | 6M Returns | 1Y Returns | 3Y Returns | 5Y Returns |
---|---|---|---|---|---|---|---|---|---|
N Nifty Healthcare | ₹ 14,468.70 | -411.55 | -2.77% | -0.18% | 3.58% | 5.03% | 4.94% | 59.96% | 59.96% |
S Sensex | ₹ 80,599.91 | -585.67 | -0.72% | -3.70% | 0.12% | 3.99% | -1.55% | 38.69% | 118.19% |
N Nifty 50 | ₹ 24,565.35 | -203.00 | -0.82% | -3.82% | 0.90% | 4.61% | -1.78% | 41.67% | 125.54% |
B BSE 100 | ₹ 25,730.72 | -231.06 | -0.89% | -3.92% | 1.34% | 4.41% | -2.75% | 45.20% | 134.10% |
N NIFTY 100 | ₹ 25,149.60 | -230.90 | -0.91% | -3.85% | 1.21% | 4.54% | -3.49% | 42.91% | 127.47% |
N NIFTY 500 | ₹ 22,673.65 | -241.30 | -1.05% | -3.99% | 3.03% | 5.06% | -3.54% | 52.72% | 153.85% |
B BSE 500 | ₹ 35,598.07 | -383.67 | -1.07% | -3.90% | 2.81% | 4.84% | -4.13% | 50.52% | 151.00% |
S Sensex Next 50 Index | ₹ 81,866.78 | -899.39 | -1.09% | -4.30% | 3.19% | 4.96% | -4.28% | 66.97% | 66.73% |
N NIFTY Midcap 150 | ₹ 21,088.65 | -272.65 | -1.28% | -3.93% | 6.84% | 6.65% | -2.85% | 85.57% | 259.24% |
N Nifty Next 50 | ₹ 66,192.80 | -903.35 | -1.35% | -3.97% | 2.74% | 4.24% | -10.91% | 59.50% | 147.67% |
N Nifty Midcap Select | ₹ 12,668.25 | -198.85 | -1.55% | -5.57% | 5.77% | 6.77% | -1.46% | 76.11% | 63.73% |
N NIFTY Smallcap 250 | ₹ 16,863.25 | -281.00 | -1.64% | -5.06% | 9.83% | 5.69% | -5.40% | 88.73% | 65.03% |
Name | LTP | Change% | High | Low |
---|---|---|---|---|
N Nifty Healthcare | ₹ 14,468.70 | -2.77% | ₹ 14,847.90 | ₹ 14,447.50 |
![]() F Fortis Healthcare | ₹ 859.25 | 0.21% | ₹ 867.35 | ₹ 849.75 |
![]() M Max Healthcare Institute | ₹ 1,246.00 | - | ₹ 1,258.20 | ₹ 1,239.00 |
![]() M Mankind Pharma | ₹ 2,566.30 | -0.04% | ₹ 2,652.70 | ₹ 2,558.90 |
![]() S Syngene International | ₹ 703.25 | -1.51% | ₹ 714.35 | ₹ 700.15 |
![]() I IPCA Laboratories | ₹ 1,450.20 | -1.61% | ₹ 1,489.40 | ₹ 1,439.30 |
![]() T Torrent Pharmaceuticals | ₹ 3,678.20 | -1.70% | ₹ 3,740.90 | ₹ 3,642.00 |
![]() A Apollo Hospitals | ₹ 7,351.50 | -1.95% | ₹ 7,538.00 | ₹ 7,331.50 |
![]() B Biocon | ₹ 383.10 | -2.12% | ₹ 392.85 | ₹ 381.80 |
![]() Z Zydus Life Science | ₹ 949.05 | -2.14% | ₹ 970.75 | ₹ 946.35 |
![]() A Abbott | ₹ 33,595.00 | -2.35% | ₹ 34,815.00 | ₹ 33,205.00 |
Date | Stock Name | Event | LTP (1D Change%) | Details |
---|---|---|---|---|
4th Aug 2025, Monday | ||||
![]() A Aurobindo Pharma | ₹ 1,101.40 (-5.26%) | Q1 FY 25-26 Results | ||
5th Aug 2025, Tuesday | ||||
![]() L Lupin | ₹ 1,930.85 (-3.20%) | Q1 FY 25-26 Results | ||
6th Aug 2025, Wednesday | ||||
![]() D Divis Laboratories | ₹ 6,618.65 (-3.55%) | Q1 FY 25-26 Results | ||
7th Aug 2025, Thursday | ||||
![]() B Biocon | ₹ 372.05 (-2.12%) | Q1 FY 25-26 Results | ||
8th Aug 2025, Friday | ||||
![]() A Alkem Laboratories | ₹ 5,265.65 (-2.63%) | Final Dividend of ₹8 Per Share | ||
11th Aug 2025, Monday | ||||
![]() I IPCA Laboratories | ₹ 1,462.05 (-1.61%) | Q1 FY 25-26 Results | ||
12th Aug 2025, Tuesday | ||||
![]() A Apollo Hospitals | ₹ 7,352.50 (-1.95%) | Q1 FY 25-26 Results | ||
![]() G Granules | ₹ 468.90 (-4.87%) | Q1 FY 25-26 Results |
A
Aurobindo Pharma
Event
LTP (1D Chg%)
₹ 1,101.40 (-5.26%)
Details
L
Lupin
Event
LTP (1D Chg%)
₹ 1,930.85 (-3.20%)
Details
D
Divis Laboratories
Event
LTP (1D Chg%)
₹ 6,618.65 (-3.55%)
Details
B
Biocon
Event
LTP (1D Chg%)
₹ 372.05 (-2.12%)
Details
A
Alkem Laboratories
Event
LTP (1D Chg%)
₹ 5,265.65 (-2.63%)
Details
I
IPCA Laboratories
Event
LTP (1D Chg%)
₹ 1,462.05 (-1.61%)
Details
A
Apollo Hospitals
Event
LTP (1D Chg%)
₹ 7,352.50 (-1.95%)
Details
G
Granules
Event
LTP (1D Chg%)
₹ 468.90 (-4.87%)
Details
The above dates are ex-dates.
View All Stock EventsThere are no Open IPOs at the moment.
Pay Zero Brokerage on Delivery
Open FREE Demat Account
+91
Or Scan the QR Code to download the Dhan App
Explore | Sitemap
*All securities mentioned on this website are exemplary and not recommendatory.
*Current prices on the website are delayed by 15 mins, login to check live prices.
We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.
Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.
That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.
©2021-2025 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services.
In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.
Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.
DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances
Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit
Attention investors:
Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.
Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.
Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/
Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX
Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets